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 INTRODUCTION 
 Quinine (QN), a natural compound found in  Cinchona 
bark, used for four centuries in malaria endemic regions, is still 
a major antimalarial drug, especially to treat severe malaria 
cases or malaria in pregnant women. Although the first cases 
of quinine resistance were reported nearly 100 years ago in 
Brazil  1  ,  2  and sporadic observations of clinical failures have 
been successively reported since the 1960s from Asia (Thai-
Cambodian border),  3  Western Oceania, or South America,  4  
the emergence and spreading of resistance to QN remained 
particularly low in comparison to other antimalarials as chlo-
roquine or antifolates. 
 Contrary to those more recent and synthetic drugs, the 
mechanisms of parasite resistance to QN are not well known. 
Some polymorphisms in multiple transporters and in the 
 Plasmodium falciparum chloroquine resistance transporter 
gene ( Pfcrt ) have been associated with QN resistance.  4  How-
ever, the degree of implication or linkage of those genes in 
QN resistance remains uncertain. Another candidate gene 
involved in  in vitro QN resistance, the  P. falciparum Na+/
H+ exchanger ( Pfnhe-1 ) gene (PF13_0019), was identified by 
Ferdig and others in 2004.  5  The physiological contribution of 
PfNHE-1 in QN resistance is still evaluated and debated, and 
could be strain-dependent.  6  Concomitantly, the evaluation of 
the association of polymorphisms in PF13_0019 with QN sus-
ceptibility is under progress. The princeps study by Ferdig and 
others described three point polymorphisms at three separate 
codons (790, 894, 950) and microsatellite variations in three 
different repeat sequences (msR1, ms3580, ms4760). Only 
variations in ms4760 showed significant association with  in 
vitro QN response in 71  P. falciparum lines. Among the eight 
profiles of ms4760 described, one profile, the ms4760-1, was 
relatively frequent in less quinine-susceptible lines but was 
also present in fully susceptible parasites. More interestingly, 
the number of a DNNND repeat motif, shared by the different 
ms4760 profiles, was reported as associated with QN response. 
Since then, another study investigated the association of poly-
morphisms in PF13_0019 with  in vitro QN susceptibility.  7  In 
that series of 23 culture-adapted isolates or reference strains, 
the relationship between the number of DNNND repeats and 
the inhibitory concentration 50% values (IC 50 ) to QN was 
confirmed and the increased number of another repeat motif, 
NHNDNHNNDDD, was associated with decreased IC 50s to 
QN. A limitation of those previous studies was that the  in vitro 
QN susceptibility and polymorphisms determinations were 
performed on culture-adapted cloned isolates or reference 
strains, which could lead to biased results caused by accumu-
lated mutations selected by  in vitro conditions. 
 In this study, we have tried to test, in isolates originating 
from various African countries, the association of the previ-
ously reported polymorphisms of PF13_0019 with  in vitro QN 
response. Fresh isolates obtained from symptomatic, malaria-
infected travelers returning from Africa to France or from 
subjects living in Madagascar were used. 
 MATERIALS AND METHODS 
 Reference culture-adapted strains.  Three culture-adapted 
and cloned strains of  P. falciparum (chloroquine-resistant 
and chloroquine-susceptible strains) were used for quality 
control (3D7Africa and W2 Indochina in Paris; 3D7Africa 
and FCM29 Cameroon in Madagascar). These clones were 
obtained from MR4-ATCC (Manassas, VA). Reference strains 
were cryopreserved and thawed before each measurement. 
They were cultivated in erythrocytes resuspended in RPMI 
1640 medium supplemented with 10% human serum (Abcys 
Biowest, Paris, France) at 37°C in a 5% CO 2 , 5% O 2 , 90% N 2 
atmosphere until a minimum parasite density of 1% was 
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achieved . The  in vitro susceptibilities to chloroquine (CQ) and 
QN were determined after suspension in the same medium 
and addition of uninfected erythrocytes to obtain 0.3% 
parasitemia and 1.5% hematocrit. The culture obtained within 
three asexual cycles after thawing contained a minimum of 
90% ring forms and did not require synchronization. 
 Patients and clinical samples.  Clinical isolates of  P. falciparum 
from symptomatic malaria-infected travelers returning to 
France from various African countries in 1997–2007 were 
obtained at the National Reference Center for Malaria 
(NRCM), Paris, France. Clinical samples from Madagascar 
were collected, as part of the surveillance of antimalarial drug 
resistance, in 2006/2007 from symptomatic patients before 
treatment in six health centers. The health centers were 
located in areas exhibiting three of the four epidemiological 
patterns of malaria transmission: Ihosy in South Madagascar 
(sub-desert stratum, epidemic prone), Maevatanana and 
Miandrivazo in West Madagascar (tropical stratum, seasonal 
and endemic area), and Tsiroanomandidy, Saharevo, and 
Moramanga in the foothills of the Central Highlands of 
Madagascar (highlands stratum, low-endemic area). Venous 
blood samples (10 mL) were collected in tubes coated with 
EDTA (Vacutainer tubes, Becton Dickinson, Rutherford, NJ), 
from malaria-positive patients (> 2 years of age). Parents or 
guardians gave their consent for participation in the study 
(No. 007/SANPF/2007, registration number from the Ethics 
Committee of the Ministry of Health of Madagascar). Malaria 
positivity was evaluated by using a rapid diagnostic test based 
on the detection of  Plasmodium -specific lactate dehydrogenase 
(pLDH) (OptiMAL-IT, DiaMed AG, Cressier sur Morat, 
Switzerland). Positive patients were treated with artesunate-
amodiaquine combination, according to the National Malaria 
Control Program (NMCP) in Madagascar. 
 Determination of QN and CQ  in vitro IC 50s .  At the NMRC, 
the determinations of IC 50s were routinely done on fresh 
isolates as part of the surveillance of antimalarial susceptibility 
of  P. falciparum isolates obtained in travelers returning to 
France.  In vitro assays performed on isolates obtained at 
the NRMC, Paris, France and at the Malaria Research Unit 
(MRU), Institut Pasteur de Madagascar, Antananarivo, Mada-
gascar were processed using the isotopic microtest method.  8  ,  9  
Antimalarial drugs in the appropriate solvent were distributed 
on 96-well tissue culture plates and dried: chloroquine disulfate 
(Sigma Aldrich, Saint-Quentin Fallavier, France), 12 to 3,200 nM 
(NCRM, Paris) or 12.5 to 1,600 nM (MRU, Antananarivo) and 
quinine (Sigma Aldrich), 25 to 3,200 nM (NCRM, Paris and 
MRU, Antananarivo). For each drug tested, three control wells 
were drug free, and each concentration was studied in duplicate 
or triplicate. Clinical isolates with at least a 0.1% parasite 
density were included in the study and were maintained at +4°C 
(for up to 48 h after collection) before a culture was started. 
The blood samples were washed three times with a solution 
of RPMI 1640 (Gibco, Invitrogen Life Technologies , Cergy-
Pontoise, France) plus 25 mM HEPES (Sigma) and 25 mM 
NaHCO 3 (Sigma). The blood samples were then resuspended 
in the same culture medium supplemented with 10% human 
serum (Abcys Biowest, Paris, France). If necessary, a dilu-
tion was performed by adding uninfected O-positive-group 
erythrocytes (from Etablissement Français du Sang, Rungis, 
France, or from Blood Transfusion Center, Antananarivo, 
Madagascar) to obtain a 0.3% parasite density and a 1.5% 
hematocrit. For  in vitro isotopic microtest, 200 μL/well of the 
suspension of parasitized erythrocytes were distributed in 
96-well plates predosed with antimalarial agents. Plates 
were incubated for 42 h at 37°C in an atmosphere of 5% O 2 , 
5% CO 2 , and 90% N 2 , and a relative humidity of 95%. Plates 
were then frozen and kept at −20°C. 
 Isotopic measurement.  For the isotopic assay, 1 mL RPMI 
1640 with [8- 3 H] hypoxanthine (40 mCi/L; Amersham Biosci-
ences, Orsay, France) was added to 20 mL of the homogeneous 
parasite suspension (~0.4 μCi [8- 3 H]hypoxanthine/well) at the 
beginning of the  in vitro assay. After the plates were thawed, 
the content of each well was harvested onto fiber filter disks 
(FilterMAT, Wallac, Turku, Finland). The fiber filter papers were 
washed and dried and mixed with 2 mL of scintillation fluid 
(OptiScint, Perkin-Elmer; NBCS 204, Amersham Biosciences, 
Orsay, France), and the level of parasite incorporation of 
radioactivity (in counts per minute) was measured with a 
liquid scintillation counter (Wallac 1410; Perkin-Elmer). The 
IC 50s were determined by nonlinear regression analysis with an 
inhibitory sigmoid maximum-effect model.  8  ,  9  The cut-off values, 
defined as > 2 SD above the mean and/or after correlation with 
clinical failures, for  in vitro resistance or reduced susceptibility 
to CQ and QN, were 100 and 800 nM, respectively. 
 Genotyping of Pfnhe ms4760 microsatellite polymorphisms 
and of Pfcrt codon76.  Parasites DNA from 100 μL infected 
blood were extracted using the phenol chloroform method 
as described elsewhere.  10  The polymerase chain reaction 
(PCR) genotyping of highly polymorphic genetic markers was 
performed to select monoclonal isolates. The polymorphic 
regions of  msp-1 (block2) and  msp-2 (block3) were amplified 
by nested PCR. Second-round appropriate PCR primers were 
used to amplify the K1, MAD20, and RO33 allelic families of 
 msp-1 and the 3D7 and FC27 allelic families of  msp-2 . The 
primers and conditions used for amplifications were those 
previously reported by Ranford-Cartwright and others.  11  
For each sample, 25 μL reactions mixtures were prepared 
containing 1X PCR buffer, 150 μM of each dNTPs, 100 nM of 
each primer, and 1.25 U of Amplitaq Gold (Applied Biosystems, 
Roche ). Five microliters (5 μL) of sample DNA were used for 
outer amplification and 2 μL of the outer PCR product was 
transferred as template for the nested amplification. Eight 
microliters (8 μL) of nested PCR products were analyzed 
by electrophoresis using 2% agarose gels. Isolates showing 
only one band in each marker were processed for further 
genotyping studies including genotyping of  Pfnhe-1 ms4760 
microsatellite polymorphisms and of  Pfcrt codon76. 
 For  Pfnhe-1 , the inner amplification reaction mixture 
contained 1X PCR buffer, 2.5 mM MgCl 2 , 1 mM of dNTPs, 
and 0.25 μM of primers (NHE-1: 5′-TCCTGATAGTAGCG
AAGAAGAA-3′ and NHE-2: 5′-CAGTGCATGGACCAA
AATTA-3′). Reactions were carried out in 25 μL and 1.25 U 
DNA polymerases (ExTaq, TaKaRa Bio Inc, Japan). The outer 
PCR was carried out in 55 μL with identical mixture with nested 
primers (NHE-3: 5′-AGTCGAAGGCGAATCAGATG-3′ and 
NHE-4: 5′-CCTGAACAAGCACTGCAAGA-3′). The PCR 
conditions used to genotype codon 76 of  Pfcrt were as pre-
viously described.  12  After purification by filtration using 
Macherey-Nagel plate (NucleoFast 96 PCR, Macherey-Nagel, 
Düren, Germany), sequencing reactions were carried out 
with the ABI PRISM BigDye Terminator cycle sequencing 
ready reaction kit run on a 3730xl Genetic Analyser (Applied 
Biosystems, Courtaboeuf, France). Electrophoregrams were 
visualized and analyzed with CEQ2000 Genetic Analysis 
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System software (Beckman Coulter, Sykesville, MD). Amino-
acid sequences were compared with wild-type sequence 
(GenBank accession no. XM_001349726 for  NHE-1 gene). 
 Pfnhe-1 ms4760 microsatellite genotypes were constructed 
from full sequence presenting an unambiguous single allele 
signal at all positions. 
 Statistical analysis.  Epi Info software (version 6.04, CDC, 
Atlanta, GA) and MedCalc software (version 9.1.0.1, Mari-
akerke, Belgium) were used for data analysis. Continuous 
variables were compared using an independent-sample analysis 
of variance (ANOVA) or Mann-Whitney test. The CQ and 
QN geometric means IC 50s were analyzed with respect to 
location of the isolates collection, polymorphism in  Pfcrt 
gene,  Pfnhe-1 ms4760 profiles (only the four most numerous 
profiles were included in the analysis), number of DNNND or 
NHNDNHNNDDD repeats or repeats ratio. A  P value < 0.05 
was considered statistically significant. For the multivariate 
analysis, variables with a  P value < 0.25 were initially introduced 
into the model and removed following a backward-stepwise 
selection procedure to leave only those with a  P value < 0.05 
in the final model. 
 Nucleotide sequence accession numbers.  The exact sequence 
of each new ms4760 genotype has been submitted to GenBank 
(accession no. FJ947067 to FJ947073). 
 RESULTS 
 A total of 83 isolates from Madagascar ( N = 40) and from 13 
other African countries (36 from West Africa, 6 from Central 
Africa, 1 from East Africa), collected between 1997 and 2007, 
appearing monoclonal on the basis of  msp-1 / msp-2 genotyp-
ing and with  Pfnhe-1 full sequences presenting only one single 
allele at all positions, were included in the study ( Table 1 ). The 
 Pfcrt 76T mutant-type allele was present in 30 isolates (36.1%) 
and its prevalence distribution was significantly heteroge-
neous: from 66.7% to 100% in mainland Africa and absent in 
Madagascar ( P < 0.0001). 
 The quality controls of batches of plates using refer-
ence lines were as follow: (IC 50s geometric mean ± SD): 
for CQ, 3D7 Africa, 28 nM ± 10 nM ( N = 116, Paris) 
and 13 nM ± 3 nM ( N = 5, Madagascar), W2 Indochina, 
389 nM ± 106 nM ( N = 154, Paris) and FCM29 Cameroon, 
216 nM ± 19 nM ( N = 5, Madagascar); for QN, 3D7 Africa, 
130 nM ± 52 nM ( N = 43, Paris) and 138 nM ± 30 nM ( N = 5, 
Madagascar), W2 Indochina, 455 nM ± 177 nM ( N = 68, Paris) 
and FCM29 Cameroon, 372 nM ± 86 nM ( N = 5, Madagascar). 
 The IC 50 median  in vitro activities of drugs were 137 nM 
for QN (confidence interval [CI] 95%: 107–183 nM, range: 
22–1,600 nM) and 74 nM for CQ (CI 95%: 51–89 nM, range: 
3–498 nM), respectively. Contrary to CQ ( P = 0.07), the QN IC 50 
geometric means displayed significant differences ( P = 0.002) 
ranging from 121 nM from Madagascar ( N = 40) to 171 nM 
from West Africa ( N = 36), 315 nM from Central Africa 
( N = 6), and 1600 nM from East Africa ( N = 1). 
 Nineteen different ms4760 microsatellite profiles of  Pfnhe-1 
were found including 14 not previously described ( Figure 1 ). 
The profiles ms-1 (31.3%), ms-3 (19.3%), ms-7 (16.9%), and 
ms-6 (8.4%) were the most common. No significant associa-
tions were noticed between the  Pfnhe-1 profiles and the geo-
graphical origin of the isolate collection ( P = 0.4). The number 
of DNNND repeats ranged from 0 to 3 (median = 2; 48.2% 
of the isolates), whereas the number of NHNDNHNNDDD 
repeats ranged from 1 to 3 (median = 2; 61.5% of the isolates) 
( Table 1 ). The median of the DNNND: NHNDNHNNDDD 
repeats ratio was 1 (range: 0–3). 
 In univariate analysis, the CQ IC 50 geometric mean was sig-
nificantly associated with the  Pfcrt polymorphism ( P < 0.0001, 
50 nM for  Pfcrt K76 versus 138 nM for  Pfcrt 76T), and the 
QN IC 50 geometric mean was significantly associated with the 
 Pfcrt polymorphism ( P = 0.001, 121 nM for  Pfcrt K76 versus 
242 nM for  Pfcrt 76T), the number of NHNDNHNNDDD 
repeats ( P = 0.02, 117 nM for one repeat and 192 nM for two 
repeats) and the location of the samples collection (as previously 
shown). There was no significant association between  in vitro QN 
susceptibility and the number of DNNND repeats ( P = 0.4). 
 In the multivariate analysis performed to control confound-
ing factors, five variables ( Pfcrt polymorphism, number of 
NHNDNHNNDDD repeats, DNNND/NHNDNHNNDDD 
repeats ratio, ms4760 microsatellite profiles, and location of 
the sample collection) were initially introduced into the model. 
Backward stepwise selection procedure to leave only variables 
with a  P value < 0.05 in the final model showed that the remain-
ing significant associations were the  in vitro susceptibility to 
CQ with the  Pfcrt polymorphism ( P < 0.001) and the  in vitro 
susceptibility to QN with the number of NHNDNHNNDDD 
repeats ( P = 0.01). 
 DISCUSSION 
 Because no valid molecular marker of QN resistance is cur-
rently available, the identification of genes potentially involved 
in QN resistance is of paramount importance to develop new 
tools for the surveillance of emergence and spreading of 
 P. falciparum -resistant strains. The finding of association of 
polymorphisms in putative genes with clinical failures and/or 
 in vitro susceptibility constitutes a pivotal step in this process. 
Such associations must be verified on numerous isolates origi-
nating from various geographical areas and further molecular 
studies are required to assess the involvement of the candidate 
genes in drug resistance. Recent genetic and physiological stud-
ies reinforced the observation that QN resistance is a complex 
trait requiring multiple factors;  6  those studies did not exclude 
a potential role for PfNHE in QN resistance, but in a strain-
dependent manner. The recent study of microsatellite markers 
flanking  Pfnhe-1 gene reported an absence of selective sweep 
in 108 Indian  P. falciparum isolates and also a lack of associa-
tion of microsatellite markers with DNNND repeats,  13  possi-
bly indicating that there is no strong selection pressure on this 
target gene. In this context, the validity and reliability of can-
didate polymorphisms in  Pfnhe-1 gene as molecular markers 
of QN resistance has to be carefully evaluated. 
 In this study, we have compiled  in vitro susceptibility data 
from France and from Madagascar to perform statistical tests 
for association. As shown by the IC 50s values of reference lines 
used as quality controls, both drug testing sites had compara-
ble results and reproducibility, which enabled us to merge the 
two sets of data for analysis. We noticed that isolates having 
the highest values of QN IC 50s (> 600 nM) had also a mutant 
allele in codon 76 of  Pfcrt ( associated with CQ resistance). The 
significant relationship found in univariate analysis between 
 in vitro QN response and the polymorphism in codon 76 of 
 Pfcrt was consistent with that found by Ferdig and others.  5  
Henry and others  7  did not report such an association though 
all strains of their series having QN IC 50s > 400 nM, except one, 
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 Table 1 
 Characteristics (country and year of collection,  in vitro susceptibility, and  Pfcrt codon 76 and  Pfnhe -1 polymorphisms) of the 83  Plasmodium falci-
parum isolates from African countries collected in 1997–2007 
Isolates Country Year of collection  Pfcrt codon76 † 
 In vitro susceptibility, 
CI 50 (nM) * 
 Pfnhe-1 ms4760 microsatellite
QN CQ No. DNNND repeat
No. NHNDNHNNDDD 
repeat No. genotype profile ‡ 
565 Mozambique 1997 76T 1600 ND 2 2 ms-1
1785 Togo 1999 76T 1267 ND 3 1 ms-7
1648 Benin 1999 76T 1191 111 1 2 ms-20
1563 Ivory Coast 1999 76T 1179 64 2 2 ms-1
5805 Cameroon 2005 76T 855 498 2 2 ms-1
1553 DRCongo 1999 76T 821 67 2 1 ms-28
TDD01 Madagascar 2006 76K 612 138 1 2 ms-3
4274 Guinea 2003 76T 611 ND 2 2 ms-1
TDD02 Madagascar 2007 76K 435 50 2 2 ms-1
6268 Mali 2006 76K 413 30 1 2 ms-3
IHO01 Madagascar 2007 76K 393 47 2 2 ms-1
MOR01 Madagascar 2006 76K 385 ND 2 2 ms-1
6569 Mali 2006 76T 371 77 2 2 ms-26
MIA01 Madagascar 2006 76K 363 104 2 2 ms-1
TDD03 Madagascar 2006 76K 353 30 1 2 ms-3
5813 DRCongo 2005 76T 330 237 3 2 ms-23
TDD04 Madagascar 2006 76K 327 38 3 1 ms-7
6643 Mali 2006 76T 310 216 1 2 ms-3
6562 Mali 2006 76T 299 167 1 2 ms-3
6685 Mali 2006 76K 285 55 1 2 ms-3
TDD05 Madagascar 2006 76K 275 ND 1 2 ms-3
6514 Mauritania 2006 76K 266 43 2 1 ms-6
3406 DRCongo 2002 76T 260 63 1 2 ms-3
MIA02 Madagascar 2006 76K 247 63 2 2 ms-1
MAE01 Madagascar 2006 76K 240 47 2 1 ms-6
MOR02 Madagascar 2006 76K 222 27 2 2 ms-1
MIA03 Madagascar 2006 76K 222 86 0 2 ms-33
MIA04 Madagascar 2006 76K 221 14 2 2 ms-1
6339 Burkina Faso 2006 76T 196 163 2 2 ms-1
4627 Ivory Coast 2004 76T 187 ND 1 2 ms-24
4275 Cameroon 2003 76T 186 ND 1 2 ms-3
MIA05 Madagascar 2006 76K 185 42 1 2 ms-31
6534 Niger 2006 76T 177 187 2 2 ms-1
5864 Senegal 2005 76T 176 52 2 2 ms-1
MIA06 Madagascar 2006 76K 166 51 1 2 ms-3
6410 Mali 2006 76T 163 139 1 2 ms-3
6588 Mali 2006 76K 159 40 3 1 ms-7
6529 Mali 2006 76T 150 114 2 2 ms-1
5773 Mali 2005 76T 145 154 2 1 ms-25
5832 Ivory Coast 2005 76T 144 294 2 2 ms-1
5774 Senegal 2005 76K 142 40 3 1 ms-7
5833 Benin 2005 76T 137 231 2 1 ms-21
5769 Burkina Faso 2005 76K 135 37 2 3 ms-22
MIA07 Madagascar 2006 76K 125 57 3 1 ms-7
MIA08 Madagascar 2006 76K 125 127 3 1 ms-7
MIA09 Madagascar 2006 76K 123 140 2 2 ms-1
5693 Ivory Coast 2005 76K 123 74 2 1 ms-21
6506 Burkina Faso 2006 76T 115 173 2 1 ms-6
MIA10 Madagascar 2007 76K 112 48 1 2 ms-30
SHV01 Madagascar 2006 76K 110 84 3 1 ms-7
6340 Mali 2006 76T 109 ND 2 2 ms-1
6481 Mali 2006 76T 107 188 2 2 ms-1
MIA11 Madagascar 2006 76K 106 74 1 2 ms-3
IHO02 Madagascar 2007 76K 105 67 1 2 ms-3
6539 Mali 2006 76T 105 120 3 2 ms-27
MIA12 Madagascar 2006 76K 105 79 2 1 ms-32
5322 Benin 2005 76T 104 138 2 2 ms-1
6612 Mali 2006 76K 104 35 1 3 ms-12
6126 Niger 2006 76T 103 212 2 2 ms-1
MIA13 Madagascar 2006 76K 102 85 2 2 ms-1
6659 Mali 2006 76K 97 22 1 2 ms-3
MIA14 Madagascar 2006 76K 96 63 2 1 ms-29
6532 Mali 2006 76K 94 39 1 3 ms-12
MIA15 Madagascar 2007 76K 92 25 3 1 ms-7
IHO03 Madagascar 2007 76K 90 33 2 1 ms-6
6430 Chad 2006 76K 88 29 1 2 ms-3
SHV02 Madagascar 2006 76K 87 126 2 1 ms-6
(Continued)
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had also a mutant allele in codon 76 of  Pfcrt . Although some 
CQ IC 50s were not performed in our series, results of genotyp-
ing of codon 76 of  Pfcrt were consistent with the measured 
CQ IC 50s in French isolates. 
 12  A particularity of Malagasy iso-
lates at this point is that  Pfcrt mutant alleles are almost totally 
absent from Madagascar  14  ,  15  and thus  in vitro CQR Malagasy 
isolates did not present this type of mutations, but they fre-
quently have single nucleotide polymorphisms (SNPs) in the 
 Pfmdr1 gene.  15  ,  16  
 The discovery of the different ms4760 microsatellite profiles 
of  Pfnhe-1 appeared as a burgeoning process as we reported 
14 not previously described, which added to the many already 
known polymorphisms in this locus.  5  ,  7  ,  17  The only association 
revealed by the multivariate analysis of our study, except the 
already known  Pfcrt 76/ in vitro CQ response association, 
was that of the number of NHNDNHNNDDD repeats with 
increased QN IC 50s geometric mean. These results were con-
flicting with those of Henry and others,  7  who reported an asso-
ciation of a greater number of NHNDNHNNDDD repeats 
with decreased QN IC 50s . We did not confirm the previously 
reported associations of particular ms4760 profiles with  in 
vitro QN response. Indeed, the ms4760-1 that was found by 
Ferdig and others  5  as associated with higher QN IC 50s was not 
confirmed by Henry and others who claimed that strains hav-
ing another particular profile (ms4760-7) had reduced suscep-
tibility to QN. In our series, isolates having either ms4760-1 or 
ms4760-7 had not particularly reduced susceptibility to QN. 
We did not confirm either the previously reported associations 
of the number of DNNND repeats with  in vitro QN response. 
 Some hypotheses may explain our data. First, the associa-
tions previously reported could be geographically restricted 
for a part. Thus, among the 15 less susceptible strains of the 
 Figure 1.  Multiple amino acid sequence alignment of the 19  pfnhe-1 ms4760 microsatellite observed in 83  Plasmodium falciparum isolates col-
lected in African countries between 1997 and 2007.The  pfnhe-1 ms4760 microsatellite sequences from ms-1 to ms-12 were previously described.  2  ,  12  
The DNNND and NHNDNHNNDDD repeats, previously associated with the  in vitro quinine susceptibility are shown in the gray box. The number 
of isolates for each profile is given on the right. 
 *  QN = quinine, CQ = chloroquine. 
 †  Pfcrt 76K (wild-type allele) and  Pfcrt 76T (mutant-type allele). 
 ‡  Pfnhe-1 ms4760 microsatellite genotype profiles are detailed in  Figure 1 . 
 ND = not done. 
Isolates Country Year of collection  Pfcrt codon76 † 
 In vitro susceptibility, 
CI 50 (nM) * 
 Pfnhe-1 ms4760 microsatellite
QN CQ No. DNNND repeat
No. NHNDNHNNDDD 
repeat No. genotype profile ‡ 
MIA16 Madagascar 2007 76K 76 13 2 2 ms-1
MIA07 Madagascar 2006 76K 74 88 1 2 ms-3
5866 Mali 2005 76T 71 34 2 1 ms-6
MIA18 Madagascar 2007 76K 70 3 3 1 ms-7
MOR03 Madagascar 2006 76K 70 37 3 1 ms-7
MIA19 Madagascar 2006 76K 64 94 1 3 ms-12
SHV03 Madagascar 2006 76K 63 142 1 2 ms-31
5655 Ivory Coast 2005 76T 57 223 2 2 ms-1
SHV04 Madagascar 2006 76K 57 17 3 1 ms-7
IHO04 Madagascar 2007 76K 51 88 3 1 ms-7
6299 Burkina Faso 2006 76K 49 21 1 3 ms-12
MIA20 Madagascar 2006 76K 37 99 3 1 ms-7
6374 Mali 2006 76K 27 30 2 2 ms-1
TDD06 Madagascar 2006 76K 23 87 2 2 ms-1
MOR04 Madagascar 2007 76K 23 142 3 1 ms-7
MOR05 Madagascar 2006 76K 22 126 2 1 ms-6
Table 1
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series of Ferdig and others,  5  11 strains originated from South-
East Asia (mainly Thailand, Vietnam, and Cambodia) as only 
four strains among the 56 other more susceptible ones origi-
nated from South-East Asia. In the same way, five out the seven 
strains having the highest QN IC 50 values in the work by Henry 
and others originated from South-East Asia as none of the 16 
other more susceptible strains came from this region. Contrary 
to those previous studies, we did not include any isolate of 
Asian origin in our series. It may be underlined that at present 
 P. falciparum QN resistance is much less frequently found in 
Africa than in Asia.  4  ,  18  Second, the likely multigenic nature of 
QN resistance and the probable strain-specific relative role 
of each molecular actor may hamper the accurate detection 
of reliable association of genetic polymorphisms with  in vitro 
QN response. The contrasted results found by different teams 
about the associations of  Pfnhe-1 polymorphisms with QN 
resistance were not without recalling us about the discussed 
status of the association of  Pfmdr-1 N86Y mutation with CQ 
resistance, which fluctuated largely according to studies.  19  
 In conclusion, the studied polymorphisms in PF13_0019 did 
not appear as valid molecular markers of  in vitro QN response 
in our series of isolates originating from various African coun-
tries. At present, the study of these polymorphisms did not 
appear useful to monitor QN resistance in Africa and help 
policy markers. 
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